Oxurion NV – Data from a Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for DME presented at 2019 FLORetina Meeting

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice